Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Adipotide
Max Weight Loss14.7%
Studies2
Participants48
StatusLimited

Adipotide

Prohibitin-targeting peptide 1 (Prohibitin-TP01)

Adipotide is a revolutionary experimental vascular-targeting peptidomimetic designed to induce selective apoptosis in blood vessels supplying white adipose tissue. Also known as Prohibitin-TP01, FTPP (Fat-Targeted Proapoptotic Peptide), or TP-1, it represents a completely novel approach to weight management through direct fat cell elimination rather than appetite suppression. While clinical development was discontinued in 2019 due to nephrotoxicity concerns, preclinical studies demonstrated remarkable efficacy with up to 30% weight reduction in rodent models and 11% weight loss in primate studies over just 28 days.

Evidence-Based Combination Strategies

⚠️ COMBINATION WARNING

Safety Alert
Evidence Base:
Safety discontinuation data (2019)
N = 48 participants
Clinical Outcomes:
Clinical development terminated due to nephrotoxicity
Safety Profile:
❌ CONTRAINDICATED: Do not combine with other compounds
Implementation Protocol:
Adipotide should NEVER be combined with other peptides or medications

Supportive Care Only

Supportive Only
Evidence Base:
Preclinical safety studies
N = 200 participants
Clinical Outcomes:
Kidney protection protocols may reduce (but not eliminate) toxicity
Safety Profile:
Only supportive hydration and kidney monitoring - no active combinations
Implementation Protocol:
Aggressive hydration + twice-weekly kidney function monitoring

Research Context Only

Not Applicable
Evidence Base:
Discontinued development
N = 0 participants
Clinical Outcomes:
No safe combination protocols established
Safety Profile:
All combination research terminated due to unacceptable risk profile
Implementation Protocol:
Adipotide research discontinued - no approved combinations exist

Medical Disclaimer

CRITICAL WARNING: Adipotide clinical development was permanently discontinued due to unacceptable nephrotoxicity. All human trials were terminated early. This information is for educational purposes only. Adipotide is NOT approved for any human use and carries severe kidney damage risks. Consult healthcare providers for approved weight management alternatives.